Identification Of Cdk10 As An Important Determinant Of Resistance To Endocrine Therapy For Breast Cancer

L Altucci, R Addeo, L Cicatiello, S Dauvois, M G Parker, M Truss, M Beato, V Sica, F Bresciani, A Weisz. 17beta Estradiol Induces Cyclin D1 Gene Transcription, P36 D1 P34cdk4 Complex Activation And P105 Rb Phosphorylation During Mitogenic Stimulation Of G(1) Arrested Human Breast Cancer Cells. 1996.

H Anderson, S Bulun, I Smith, M Dowsett. Predictors Of Response To Aromatase Inhibitors. 2007.

M Baum, A Buzdar, J Cuzick, J Forbes, J Houghton, A Howell, T Sahmoud, Trialists' Group. Anastrozole Alone Or In Combination With Tamoxifen Versus Tamoxifen Alone For Adjuvant Treatment Of Postmenopausal Women With Early Stage Breast Cancer: Results Of The Atac (Arimidex, Tamoxifen Alone Or In Combination) Trial Efficacy And Safety Update Analyses. 2003.

S Cariou, J C Donovan, W M Flanagan, A Milic, N Bhattacharya, J M Slingerland. Down Regulation Of P21 Waf1/Cip1 Or P27 Kip1 Abrogates Antiestrogen Mediated Cell Cycle Arrest In Human Breast Cancer Cells. 2000.

J Dancey, E A Sausville. Issues And Progress With Protein Kinase Inhibitors For Cancer Treatment. 2003.

. Tamoxifen For Early Breast Cancer: An Overview Of The Randomised Trials. 1998.

C J Echeverri, P A Beachy, B Baum, M Boutros, F Buchholz, S K Chanda, J Downward, J Ellenberg, A G Fraser, N Hacohen. Title. 2006.

. Minimizing The Risk Of Reporting False Positives In Large Scale Rn Ai Screens.

D El-Ashry, D L Miller, S Kharbanda, M E Lippman, F G Kern. Title. 1997.

. Constitutive Raf 1 Kinase Activity In Breast Cancer Cells Induces Both Estrogenindependent Growth And Apoptosis.

J M Gee, J F Robertson, I O Ellis, R I Nicholson. Phosphorylation Of Erk1/2 Mitogen Activated Protein Kinase Is Associated With Poor Response To Anti Hormonal Therapy And Decreased Patient Survival In Clinical Breast Cancer. 2001.

E Iorns, C J Lord, N Turner, A Ashworth. Utilizing Rna Interference To Enhance Cancer Drug Discovery. 2007.

A L Jackson, J Burchard, D Leake, A Reynolds, J Schelter, J Guo, J M Johnson, L Lim, J Karpilow, K Nichols. Position Specific Chemical Modification Of Si Rn As Reduces ''Off Target'' Transcript Silencing. 2006.

S B Jakowlew, R Breathnach, J M Jeltsch, P Masiakowski, Chambon, P. Sequence Of The P S2 M Rna Induced By Estrogen In The Human Breast Cancer Cell Line Mcf 7. 1984.

M P Jansen, J A Foekens, I L Van Staveren, M M Dirkzwager-Kiel, K Ritstier, M P Look, M E Meijer-Van Gelder, A M Sieuwerts, H Portengen, L C Dorssers. Molecular Classification Of Tamoxifen Resistant Breast Carcinomas By Gene Expression Profiling. 2005.

S E Jones. A New Estrogen Receptor Antagonist An Overview Of Available Data. 2002.

V C Jordan. Studies On The Estrogen Receptor In Breast Cancer'' 20 Years As A Target For The Treatment And Prevention Of Cancer. 1995.

M Kasten, Giordano, A. Cdk10, A Cdc2 Related Kinase, Associates With The Ets2 Transcription Factor And Modulates Its Transactivation Activity. 2001.

F S Kenny, R Hui, E A Musgrove, J M Gee, R W Blamey, R I Nicholson, R L Sutherland, J F Robertson. Overexpression Of Cyclin D1 Messenger Rna Predicts For Poor Prognosis In Estrogen Receptor Positive Breast Cancer. 1999.

J N Lavoie, G L'allemain, A Brunet, R Muller, J Pouyssegur. Title. 1996.

. Cyclin D1 Expression Is Regulated Positively By The P42/P44 Mapk And Negatively By The P38/Hogmapk Pathway.

S Loi, B Haibe-Kains, C Desmedt, F Lallemand, A M Tutt, C Gillet, P Ellis, A Harris, J Bergh, J A Foekens. Definition Of Clinically Distinct Molecular Subtypes In Estrogen Receptor Positive Breast Carcinomas Through Genomic Grade. 2007.

D J Mangelsdorf, C Thummel, M Beato, P Herrlich, G Schutz, K Umesono, B Blumberg, P Kastner, M Mark, P Chambon, R M Evans. The Nuclear Receptor Superfamily: The Second Decade. 1995.

E A Musgrove, R L Sutherland. Cell Cycle Control By Steroid Hormones. 1994.

E Myers, A D Hill, G Kelly, E W Mcdermott, N J Higgins, Y Buggy, Young, L S. Associations And Interactions Between Ets 1 And Ets 2 And Coregulatory Proteins, Src 1, Aib1, And N Co R In Breast Cancer. 2005.

A S Oh, L A Lorant, J N Holloway, D L Miller, F G Kern, D El-Ashry. Hyperactivation Of Mapk Induces Loss Of E Ralpha Expression In Breast Cancer Cells. 2001.

G Pé Rez-Tenorio, O Stå L. Activation Of Akt/Pkb In Breast Cancer Predicts A Worse Outcome Among Endocrine Treated Patients. 2002.

R J Santen, R X Song, Z Zhang, R Kumar, M H Jeng, S Masamura, J Lawrence, Jr, L P Macmahon, W Yue, L Berstein. Adaptive Hypersensitivity To Estrogen: Mechanisms And Clinical Relevance To Aromatase Inhibitor Therapy In Breast Cancer Treatment. 2005.

C J Sherr. Cancer Cell Cycles. 1996.

J Shou, S Massarweh, C K Osborne, A E Wakeling, S Ali, H Weiss, R Schiff. Mechanisms Of Tamoxifen Resistance: Increased Estrogen Receptor Her2/Neu Cross Talk In Er/Her2 Positive Breast Cancer. 2004.

P Smith, L J Nicholson, N Syed, A Payne, L Hiller, O Garrone, M Occelli, M Gasco, T Crook. Epigenetic Inactivation Implies Independent Tumour Suppressor Functions For Igfbp R P1 And The Related Igfbpl1 In Breast Cancer. 2007.

S Svensson, K Jirströ M, L Rydé N, G Roos, S Emdin, M C Ostrowski, G Landberg. Erk Phosphorylation Is Linked To Vegfr2 Expression And Ets 2 Phosphorylation In Breast Cancer And Is Associated With Tamoxifen Treatment Resistance And Small Tumours With Good Prognosis. 2005.

C Swanton, M Marani, O Pardo, P H Warne, G Kelly, E Sahai, F Elustondo, J Chang, J Temple, A A Ahmed. Regulators Of Mitotic Arrest And Ceramide Metabolism Are Determinants Of Sensitivity To Paclitaxel And Other Chemotherapeutic Drugs. 2007.

A W Whitehurst, B O Bodemann, J Cardenas, D Ferguson, L Girard, M Peyton, J D Minna, C Michnoff, W Hao, M G Roth. Synthetic Lethal Screen Identification Of Chemosensitizer Loci In Cancer Cells. 2007.

N R Wilcken, O W Prall, E A Musgrove, R L Sutherland. Inducible Overexpression Of Cyclin D1 In Breast Cancer Cells Reverses The Growth Inhibitory Effects Of Antiestrogens. 1997.

E Wingender, P Dietze, H Karas, R Knuppel. Transfac: A Database On Transcription Factors And Their Dna Binding Sites. 1996.